Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena), Italy.
Int J Biol Markers. 2009 Oct-Dec;24(4):253-7. doi: 10.1177/172460080902400406.
Telomerase activity assessment in voided urine is an important noninvasive tool for bladder cancer diagnosis. In a previous case-control study we verified that this method can detect tumor cells in urine with high sensitivity and specificity, but few data are still available on its accuracy to detect tumors in patients with symptomatic urinary tract diseases. Following recently published guidelines on bladder cancer, we aimed to define the diagnostic accuracy of urine telomerase levels in symptomatic patients. Telomerase activity, expressed in arbitrary enzymatic units (AEUs), was evaluated in urine collected from 515 patients: 197 with urinary tract symptoms and 318 with a first diagnosis of bladder cancer. Telomerase repeat amplification protocol (TRAP) sensitivity ranged from 93% to 61% and specificity varied from 42% to 88% at the different AEU cutoff values. At the cutoff of 50, the sensitivity was 87% (95% CI 83-91), the specificity was 70% (95% CI 63-75), and the overall accuracy, in terms of true positives and true negatives, was 80%. Sensitivity did not vary in relation to tumor grade or stage at diagnosis, or to patient age. Our results indicate that urine telomerase activity is a good marker for the early diagnosis of bladder tumors in symptomatic patients, a subset which represents an "at-risk" population requiring close surveillance.
端粒酶活性评估在尿液中是膀胱癌诊断的重要非侵入性工具。在之前的病例对照研究中,我们验证了这种方法可以高灵敏度和特异性地检测尿液中的肿瘤细胞,但关于其在有症状的泌尿道疾病患者中检测肿瘤的准确性的数据仍然很少。根据最近发布的膀胱癌指南,我们旨在定义有症状患者尿液中端粒酶水平的诊断准确性。在 515 名患者的尿液中评估了端粒酶活性,用任意酶单位(AEU)表示:197 名有泌尿道症状,318 名首次诊断为膀胱癌。端粒酶重复扩增协议(TRAP)的灵敏度范围为 93%至 61%,在不同的 AEU 截断值下特异性范围为 42%至 88%。在 50 的截断值下,灵敏度为 87%(95%CI 83-91),特异性为 70%(95%CI 63-75),总的准确率,即真阳性和真阴性,为 80%。诊断时的肿瘤分级或分期或患者年龄与灵敏度无关。我们的结果表明,尿液端粒酶活性是有症状患者膀胱癌早期诊断的良好标志物,这是一个需要密切监测的“高危”人群。